Lv1
70 积分 2025-05-13 加入
Discovery of High-Affinity SMARCA2/4 Bromodomain Ligands and Development of Potent and Exceptionally Selective SMARCA2 PROTAC Degraders
26天前
已完结
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
1个月前
已完结
BRAF oncogenic mutants evade autoinhibition through a common mechanism
1个月前
已完结
ERα dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER+ breast cancer
1个月前
已完结
BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor-Positive Breast Cancer via Induction of miR-34a-5p
1个月前
已完结
Design and Development of DNA Damage Chemical Inducers of Proximity for Targeted Cancer Therapy
1个月前
已完结
Resistance of estrogen receptor function to BET bromodomain inhibition is mediated by transcriptional coactivator cooperativity
2个月前
已完结
Targeting lysine acetylation readers and writers
2个月前
已完结
Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia
2个月前
已完结
A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
3个月前
已完结
皖公网安备34019202002308
